Conditions: Overactive Bladder
Keywords: Solifenacin succinate Oxybutynin immediate release Xerostomia Overactive bladder
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 132
Healthy volunteers: no

Brief summary:
The purpose of this study is to compare the safety and efficacy of solifenacin with oxybutynin immediate-release (IR) for the treatment of overactive bladder (OAB).

Detailed description:
This study is a prospective randomized, double-blind, double-dummy, multicentre, 2-arm (1 Active, Active Control) comparative parallel group study to compare the safety and efficacy of solifenacin with oxybutynin immediate-release (IR) for the treatment of overactive bladder (OAB).

Arms:
arm 1: Solifenacin succinate: 5 mg tablets, taken orally, once daily arm 2: Oxybutynin Immediate Release: 5 mg capsules, taken orally, 3 times a day

Interventions: intervention 1: solifenacin intervention 2: oxybutynin immediate release
Intervention descriptions: intervention 1: Oral intervention 2: Oral

Protocol document: